Background. Ravuconazole (BMS-207147) is a novel triazole antifungal agent with broad-spectrum antifungal activity against a wide range of fungi including Aspergillus spp., Cryptococcus neoformans, and Candida spp. In this study, we compared the activity of ravuconazole (RAVU) with itraconazole (ITRA), fluconazole (FLU), and voriconazole (VORI) against 153 opportunistic filamentous and dimorphic fungi. Tested were Pseudallescheria boydii (Pb) (18), Paecilomyces lilacinus (Pl) (12), Fusarium spp. (Fus) (27), Sporothrix schenckii (Ss) (10), Fonsecaea pedrosoi (Fp) (5), Cladophialophora carrioni (Cc) (7), Coccidioides immitis (Ci) (55), Histoplasma capsulatum (Hc) (12), Blastomyces dermatitidis (Bd) (6), and Penicillium marneffei (Pm) (1). Methods. Susceptibility testing was accomplished using the NCCLS proposed standard reference method M38-P. Macro broth dilution testing was performed using an inoculum of 0.4 &multiply; 104 to 5 &multiply; 104 CFU/ml and RPMI-1640. The tests were incubated at 30 °C and read at 24, 48 and 72 hours depending the rate of fungal growth. Results. Our results showed that RAVU, ITRA, and VORI were comparably active against Ss (geometric mean of 1.13, 1.51, and 1.21 respectively); Fp (geometric mean of 0.24, 0.41, and 0.31 respectively); Cc (geometric mean of 0.39, 0.21, and 0.18 respectively); Ci (geometric mean of 0.58, 0.36, and 0.27 respectively); Hc (geometric mean of 0.68, 0.61, and 0.75 respectively) and Bd (geometric mean of 0.81, 0.73, and 0.77 respectively). In contrast, the triazoles were generally less effective in vitro against Pl and Fus. ITRA and VORI were slightly more effective in vitro against Pb than RAVU and FLU. Conclusion. These results indicate the potential clinical utility of RAVU and further clinical studies are warranted.
Full conference title:
American Society for Microbiology General Meeting
- ASM 102nd (2002)